Online citations, reference lists, and bibliographies.
← Back to Search

Comparative Efficacy And Acceptability Of 12 New-generation Antidepressants: A Multiple-treatments Meta-analysis

A. Cipriani, T. Furukawa, G. Salanti, J. Geddes, C. Barbui
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
BACKGROUND Conventional meta-analyses have shown inconsistent results for efficacy of second-generation antidepressants. We therefore did a multiple-treatments meta-analysis, which accounts for both direct and indirect comparisons, to assess the effects of 12 new-generation antidepressants on major depression. METHODS We systematically reviewed 117 randomised controlled trials (25 928 participants) from 1991 up to Nov 30, 2007, which compared any of the following antidepressants at therapeutic dose range for the acute treatment of unipolar major depression in adults: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, milnacipran, mirtazapine, paroxetine, reboxetine, sertraline, and venlafaxine. The main outcomes were the proportion of patients who responded to or dropped out of the allocated treatment. Analysis was done on an intention-to-treat basis. FINDINGS Mirtazapine, escitalopram, venlafaxine, and sertraline were significantly more efficacious than duloxetine (odds ratios [OR] 1.39, 1.33, 1.30 and 1.27, respectively), fluoxetine (1.37, 1.32, 1.28, and 1.25, respectively), fluvoxamine (1.41, 1.35, 1.30, and 1.27, respectively), paroxetine (1.35, 1.30, 1.27, and 1.22, respectively), and reboxetine (2.03, 1.95, 1.89, and 1.85, respectively). Reboxetine was significantly less efficacious than all the other antidepressants tested. Escitalopram and sertraline showed the best profile of acceptability, leading to significantly fewer discontinuations than did duloxetine, fluvoxamine, paroxetine, reboxetine, and venlafaxine. INTERPRETATION Clinically important differences exist between commonly prescribed antidepressants for both efficacy and acceptability in favour of escitalopram and sertraline. Sertraline might be the best choice when starting treatment for moderate to severe major depression in adults because it has the most favourable balance between benefits, acceptability, and acquisition cost.
This paper references
10.1097/00004714-200204000-00006
Acute Efficacy of Fluoxetine Versus Sertraline and Paroxetine in Major Depressive Disorder Including Effects of Baseline Insomnia
M. Fava (2002)
10.1023/A:1022309428886
Sexual Dysfunction Associated with the Treatment of Depression: A Placebo-Controlled Comparison of Bupropion Sustained Release and Sertraline Treatment
C. Coleman (1999)
10.1097/01.jcp.0000085408.08426.05
Mirtazapine Orally Disintegrating Tablet Versus Sertraline: A Prospective Onset of Action Study
K. Behnke (2003)
10.4088/JCP.V66N1015
Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
A. Sir (2005)
10.1007/BF02850218
Comparison of the effectiveness of reboxetine versus fluoxetine in patients with atypical depression: A single-blind, randomized clinical trial
E. Taner (2006)
10.1016/j.biopsych.2007.03.027
Are Antidepressant Drugs That Combine Serotonergic and Noradrenergic Mechanisms of Action More Effective Than the Selective Serotonin Reuptake Inhibitors in Treating Major Depressive Disorder? A Meta-analysis of Studies of Newer Agents
G. Papakostas (2007)
10.4088/JCP.V64N0810
A double-blind, randomized, group-comparative study of the tolerability and efficacy of 6 weeks' treatment with mirtazapine or fluoxetine in depressed Chinese patients.
Chen-Jee Hong (2003)
10.4088/JCP.v61n0204
Randomized, Double-Blind Comparison of Venlafaxine and Sertraline in Outpatients With Major Depressive Disorder
O. Mehtonen (2000)
10.1136/bmj.327.7414.557
Measuring inconsistency in meta-analyses
J. Higgins (2003)
10.1179/135100003225003393
Oxidative damage and major depression: the potential antioxidant action of selective serotonin re-uptake inhibitors
S. Khanzode (2003)
10.1097/01.YIC.0000194377.88330.1D
A double-blind, randomized, parallel-group, flexible-dose study to evaluate the tolerability, efficacy and effects of treatment discontinuation with escitalopram and paroxetine in patients with major depressive disorder
D. Baldwin (2006)
10.1016/0197-2456(86)90046-2
Meta-analysis in clinical trials.
R. Dersimonian (1986)
10.1016/S0924-977X(98)80329-5
Efficacy and safety of venlafaxine vs. fluvoxamine in outpatients with major depression
David L. Hackett (1998)
10.1001/JAMA.287.14.1840
Placebo response in studies of major depression: variable, substantial, and growing.
B. T. Walsh (2002)
10.1097/01.jcp.0000204138.20417.c3
Efficacy and Tolerability of Reboxetine Compared with Citalopram: A Double-blind Study in Patients with Major Depressive Disorder
S. Langworth (2006)
10.1002/HUP.470100505
A controlled comparison of sertraline and fluoxetine in acute and continuation treatment of major depression
M. V. van Moffaert (1995)
Depression: management of depression in primary and secondary care
Nice (2005)
10.4088/JCP.V59N0703
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
J. C. E. Silva (1998)
10.1001/ARCHPSYC.63.11.1217
Early onset of selective serotonin reuptake inhibitor antidepressant action: systematic review and meta-analysis.
M. Taylor (2006)
Venlafaxine vs imipramine, sertraline in treating depression
C. Zuo (2001)
10.1097/00004850-199903000-00003
Reboxetine: a double-blind comparison with fluoxetine in major depressive disorder.
J. Massana (1999)
10.1097/00004714-200012000-00010
Sertraline versus paroxetine in major depression: clinical outcome after six months of continuous therapy.
A. Åberg-Wistedt (2000)
A double-blind comparison of venlafaxine and fl uoxetine for treatment of major depression in out-patients
M Dierick (1996)
10.1016/J.JPSYCHIRES.2005.07.009
A double-blind, placebo-controlled comparison of venlafaxine and fluoxetine treatment in depressed outpatients.
C. Nemeroff (2007)
Double-blind comparison of bupropion and fluoxetine in depressed outpatients.
J. Feighner (1991)
10.1001/JAMA.289.4.454
Scope and impact of financial conflicts of interest in biomedical research: a systematic review.
J. Bekelman (2003)
10.1016/J.CCT.2006.10.012
Clinical trials and the response rate illusion.
I. Kirsch (2007)
10.1186/1478-7547-4-19
Can discrete event simulation be of use in modelling major depression?
Agathe Le Lay (2006)
[Comparison of reboxetine and sertraline in terms of efficacy and safety in major depressive disorder].
S. Eker (2005)
uoxetine in severely depressed patients
A Wade (2005)
10.2165/00044011-199714020-00001
Citalopram and Fluoxetine in Major Depression
T. Bougerol (1997)
10.1016/S0924-977X(98)80184-3
Efficacy and tolerability of venlafaxine and fluoxetine in outpatients with major depression
M. L. Figueira (1998)
10.1097/00019442-200209000-00007
Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients.
A. Schatzberg (2002)
10.1097/00004850-199606000-00007
Citalopram versus fluoxetine: a double‐blind, controlled, multicentre, phase III trial in patients with unipolar major depression treated in general practice
M. Patris (1996)
Comparison of venlafaxine XR and reboxetine in terms of effi cacy and safety in major depressive disorder
C Akkaya (1993)
10.1136/bmj.322.7280.226
Sifting the evidence—what's wrong with significance tests?
J. Sterne (2001)
Antidepressant effi cacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fl uvoxamine
G Clerc (2001)
10.1016/S0165-0327(99)00067-1
A double-blind, randomized, placebo-controlled trial of once-daily venlafaxine extended release (XR) and fluoxetine for the treatment of depression.
R. Rudolph (1999)
A double-blind, comparative study of paroxetine and fl uoxetine in out-patients with depression
A Ontiveros (1997)
10.1097/00004714-200212000-00011
Symptom Severity and Exclusion From Antidepressant Efficacy Trials
M. Zimmerman (2002)
10.4088/JCP.V61N0309
Bupropion sustained release versus paroxetine for the treatment of depression in the elderly.
K. Weihs (2000)
10.4088/JCP.V64N1013
Comparative effects of mirtazapine and fluoxetine on sleep physiology measures in patients with major depression and insomnia.
A. Winokur (2003)
10.1056/nejmc080313
Selective publication of antidepressant trials.
P. Ninan (2008)
10.1136/bmj.316.7132.690
Interpreting treatment effects in randomised trials
G. Guyatt (1998)
uoxetine in the treatment of depression
M Ansseau (2002)
10.1097/01.jcp.0000239790.83707.ab
A Double-blind Comparison Between Bupropion XL and Venlafaxine XR: Sexual Functioning, Antidepressant Efficacy, and Tolerability
M. Thase (2006)
10.1097/01.jcp.0000177548.28961.e7
Sertraline Versus Fluvoxamine in the Treatment of Elderly Patients With Major Depression: A Double-blind, Randomized Trial
D. Rossini (2005)
10.4088/JCP.V64N0804
Probing the safety of medications in the frail elderly: evidence from a randomized clinical trial of sertraline and venlafaxine in depressed nursing home residents.
D. Oslin (2003)
10.1016/S0165-0327(99)00131-7
Fluoxetine versus sertraline and paroxetine in major depression: tolerability and efficacy in anxious depression.
M. Fava (2000)
10.1097/00004714-199610000-00005
A comparison of fluvoxamine and fluoxetine in the treatment of major depression.
M. Rapaport (1996)
10.1016/J.JAD.2006.04.029
Different gender response to serotonergic and noradrenergic antidepressants. A comparative study of the efficacy of citalopram and reboxetine.
C. Berlanga (2006)
10.1016/S0165-0327(98)00188-8
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder.
G. Chouinard (1999)
A double - blind , randomized , 12 - week comparison study of the safety and effi cacy of venlafaxine and fl uoxetine in moderate to severe major depression in general - practice
A Tylee (1997)
10.1056/NEJMe0802618
Full disclosure and the funding of biomedical research.
R. Schwartz (2008)
10.1097/00004850-199409000-00001
A double‐blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia
G. Clerc (1994)
10.1192/BJP.180.5.396
Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis.
D. Smith (2002)
10.1111/j.1365-2710.2004.00585.x
Comparison of mirtazapine and fluoxetine in the treatment of major depressive disorder: a double‐blind, randomized trial
H. Amini (2005)
10.4088/JCP.V59N0606
Mirtazapine: efficacy and tolerability in comparison with fluoxetine in patients with moderate to severe major depressive disorder. Mirtazapine-Fluoxetine Study Group.
D. Wheatley (1998)
Randomized, double-blind comparison of venlafaxine and fluoxetine in outpatients with major depression.
J. A. Costa e Silva (1998)
10.1023/A:1022337927842
A Double-Blind Study of Paroxetine, Fluoxetine, and Placebo an Outpatients with Major Depression
M. Fava (1998)
10.1016/S0924-977X(97)88489-1
P.1.040 A double-blind study comparing sertraline and citalopram in patients with major depression treated in general practice
L. Ekselius (1997)
A double-blind, randomized, parallel-group
DS Baldwin (1994)
Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) Part 1: World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part I: Acute and continuation treatment of major depressive disorder
M. Bauer (2009)
10.1097/00004850-200105000-00003
Antidepressant efficacy and tolerability of milnacipran, a dual serotonin and noradrenaline reuptake inhibitor: a comparison with fluvoxamine
G. Clerc (2001)
10.1159/000078225
A Randomised Study Comparing Escitalopram with Venlafaxine XR in Primary Care Patients with Major Depressive Disorder
S. Montgomery (2004)
10.1097/01.yic.0000066456.73432.09
Lack of sexual dysfunction with the selective noradrenaline reuptake inhibitor reboxetine during treatment for major depressive disorder
A. Clayton (2003)
10.1016/j.euroneuro.2004.01.002
Duloxetine in the acute and long-term treatment of major depressive disorder: a placebo- and paroxetine-controlled trial
M. Detke (2004)
uoxetine: a systematic review
GI Papakostas (2006)
10.1002/HUP.470090502
Controlled comparison of paroxetine and fluvoxamine in major depression
M. Ansseau (1994)
10.1002/9781119536604
Cochrane Handbook for Systematic Reviews of Interventions
Michele Tarsilla (2010)
10.1097/JGP.0B013E3181256B1D
Design makes a difference: a meta-analysis of antidepressant response rates in placebo-controlled versus comparator trials in late-life depression.
J. Sneed (2008)
10.4088/JCP.V58N0402
A double-blind comparison of fluvoxamine and paroxetine in the treatment of depressed outpatients.
A. Kiev (1997)
10.1001/JAMA.287.21.2801
Quality of reporting of randomized trials as a measure of methodologic quality.
Karin Huwiler-Müntener (2002)
10.1016/J.JAD.2004.07.002
A comparative study of milnacipran and paroxetine in outpatients with major depression.
D. Sechter (2004)
10.3109/10401239809147030
A double-blind study of paroxetine, fluoxetine, and placebo in outpatients with major depression.
M. Fava (1998)
A double-blind multicenter trial comparing sertraline and fluoxetine in outpatients with major depression.
E. Bennie (1995)
First , randomized , double - blind comparison of mirtazapine ( 15 – 45 mg ) and fl uvoxamine ( 50 – 150 mg ) in the treatment of depression
J Schoemaker (2002)
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double-blind, multicentre study. The LUCIFER Group.
P. J. Haffmans (1996)
A fixed-dose clinical trial of fluoxetine in outpatients with major depression.
L. Fabre (1987)
10.1159/000094727
Effects of the Serotonin Type 2A, 3A and 3B Receptor and the Serotonin Transporter Genes on Paroxetine and Fluvoxamine Efficacy and Adverse Drug Reactions in Depressed Japanese Patients
M. Kato (2006)
10.1017/S1121189X00004577
What is a risk ratio?
A. Cipriani (2007)
10.1185/030079906X115513
A comparative study of the efficacy of long-term treatment with escitalopram and paroxetine in severely depressed patients
J. Boulenger (2006)
10.4088/JCP.V67N0601
Are all antidepressants really the same? The case of fluoxetine: a systematic review.
A. Cipriani (2006)
10.1097/00004850-199703000-00005
Milnacipran, a new serotonin and noradrenaline reuptake inhibitor: an overview of its antidepressant activity and clinical tolerability
A. Puech (1997)
10.1097/00019442-200510000-00008
Escitalopram in the treatment of depressed elderly patients.
S. Kasper (2005)
10.1017/S1461145702002857
Venlafaxine compared with fluoxetine in outpatients with depression and concomitant anxiety.
A. De Nayer (2002)
10.1097/00004714-200108000-00010
Mirtazapine Versus Venlafaxine in Hospitalized Severely Depressed Patients With Melancholic Features
J. Guelfi (2001)
Hoyberg OJ. First, randomized, double-blind comparison of mirtazapine (15–45 mg) and fl uvoxamine (50–150 mg) in the treatment of depression
J Schoemaker (2002)
10.4088/JCP.V58N1204
Double-blind comparison of bupropion sustained release and sertraline in depressed outpatients.
R. Kavoussi (1997)
10.1016/0006-3223(90)90030-6
World federation of societies of biological psychiatry
(1990)
10.1080/15622970701227829
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders in Primary Care
M. Bauer (2007)
Milnacipran versus Sertraline in Major Depressive Disorder : A Double-Blind Randomized Comparative Study on the Treatment Effect and β-Adrenergic Receptor Responsiveness
Jong-Chul Yang (2003)
10.1185/030079905X65484
A randomized, double-blind, 24‐week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive disorder*
L. Colonna (2005)
10.1016/S0924-9338(99)80714-7
A double-blind comparison of sertraline and fluoxetine in the treatment of major depressive episode in outpatients.
D. Sechter (1999)
10.2165/00023210-200519020-00004
Comparison of the Effects of Mirtazapine and Fluoxetine in Severely Depressed Patients
M. Versiani (2005)
10.1097/00004850-199300830-00010
Double‐blind study of the efficacy and safety of sertraline versus fluoxetine in major depression
E. Aguglia (1993)
10.1185/030079906X167453
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study*
A. Nierenberg (2007)
10.4088/JCP.V61N0804
A double-blind comparison of sertraline and fluoxetine in depressed elderly outpatients.
P. Newhouse (2000)
A comparison of the eff ects on sexual functioning of bupropion XL, escitalopram and placebo in outpatients with major depression
A Clayton (2004)
A double-blind, comparative, multicentre study comparing paroxetine with fl uoxetine in depressed patients
J De Wilde (1993)
10.1007/978-3-662-46875-3_102072
Selective serotonin reuptake inhibitors.
A. N. Chonchubhair (1998)
10.1185/030079905X59166
Comparison of efficacy and safety of milnacipran and fluoxetine in Korean patients with major depression
M. Lee (2005)
10.1001/JAMA.287.14.1853
Placebo in clinical trials for depression: complexity and necessity.
D. Kupfer (2002)
10.1097/00004850-200307000-00003
Escitalopram (10–20 mg/day) is effective and well tolerated in a placebo‐controlled study in depression in primary care
U. Lepola (2003)
10.4088/JCP.V65N0906
A double-blind comparison of escitalopram and venlafaxine extended release in the treatment of major depressive disorder.
R. Bielski (2004)
10.1371/journal.pmed.0050045
Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug Administration
I. Kirsch (2008)
10.1097/00004714-200208000-00010
Reboxetine, a New Noradrenaline Selective Antidepressant, Is at Least as Effective as Fluoxetine in the Treatment of Depression
V. Andreoli (2002)
10.1002/GPS.1190
Efficacy and tolerability of venlafaxine in geriatric outpatients with major depression: a double‐blind, randomised 6‐month comparative trial with citalopram
P. Allard (2004)
10.1002/HUP.490
Fluvoxamine versus fluoxetine in major depressive episode: a double‐blind randomised comparison
J. Daléry (2003)
10.1097/01.jcp.0000194622.99986.d6
Mirtazapine Orally Disintegrating Tablets Versus Venlafaxine Extended Release: A Double-blind, Randomized Multicenter Trial Comparing the Onset of Antidepressant Response in Patients With Major Depressive Disorder
O. Benkert (2006)
cacy and safety of second-generation antidepressants in the treatment of major depressive disorder
A Cipriani (2005)
10.4088/JCP.V67N0507
Bupropion extended release compared with escitalopram: effects on sexual functioning and antidepressant efficacy in 2 randomized, double-blind, placebo-controlled studies.
A. Clayton (2006)
10.1016/0278-5846(95)00292-8
A double-blind comparison of venlafaxine and fluoxetine for treatment of major depression in outpatients
Michel Dieric (1996)
10.4088/JCP.V60N0105
Once-daily venlafaxine extended release (XR) compared with fluoxetine in outpatients with depression and anxiety. Venlafaxine XR 360 Study Group.
P. Silverstone (1999)
10.3310/HTA11140
A systematic review and economic evaluation of statins for the prevention of coronary events.
S. Ward (2007)
10.1185/030079906X167273
Escitalopram versus sertraline in the treatment of major depressive disorder: a randomized clinical trial*
Daniel Ventura (2007)
uoxetine in moderate to severe major depression in general-practice
M Tzanakaki (1997)
10.1016/S0149-2918(01)80090-4
A placebo-controlled comparison of the effects on sexual functioning of bupropion sustained release and fluoxetine.
C. C. Coleman (2001)
Bupropion XL compared with escitalopram: eff ects on sexual functioning and antidepressant effi cacy in two randomized, double-blind, placebo controlled studies
AH Clayton (2006)
10.7326/0003-4819-143-6-200509200-00006
Efficacy and Safety of Second-Generation Antidepressants in the Treatment of Major Depressive Disorder
R. Hansen (2005)
10.1097/00004850-200505000-00002
Prospective, multicentre, randomized, double-blind study of the efficacy of escitalopram versus citalopram in outpatient treatment of major depressive disorder
N. Moore (2005)
10.1176/FOC.8.4.FOC592
Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIs
C. Nemeroff (2010)
10.1016/S0924-977X(02)80231-0
Duloxetine in the treatment of depression: A double-blind placebo-controlled comparison with paroxetine
C. Mallinckrodt (2002)
10.1016/J.EURPSY.2006.03.004
Duloxetine in the treatment of major depressive disorder: a placebo- and paroxetine-controlled trial.
D. Perahia (2006)
uvoxamine in major depression
M Ansseau (1994)
10.1097/01.jcp.0000115665.45074.0d
"Wish Bias" in Antidepressant Drug Trials?
C. Barbui (2004)
10.1016/S0006-3223(00)00957-4
Placebo-controlled comparison of the selective serotonin reuptake inhibitors citalopram and sertraline
S. Stahl (2000)
Comparative eff ectiveness of second - generation antidepressants in the pharmacologic treatment of adult depression . Comparative eff ectiveness review no 7
G Gartlehner (2007)
10.1016/S0149-2918(98)80056-8
A randomized, open-label comparison of venlafaxine and fluoxetine in depressed outpatients.
A. Diaz-martinez (1998)
10.4088/JCP.V63N0309
Duloxetine in the treatment of major depressive disorder: a double-blind clinical trial.
D. Goldstein (2002)
10.1176/AJP.153.12.1631
Double-blind controlled trial of sertraline versus paroxetine in the treatment of delusional depression.
R. Zanardi (1996)
10.1016/S0924-977X(97)88532-X
P.1.083 A comparison of once-daily venlafaxine XR and paroxetine in depressed outpatients treated in general practise
G. M. McPartlin (1997)
10.1185/030079907X210732
A comparative study of the efficacy of acute and continuation treatment with escitalopram versus duloxetine in patients with major depressive disorder
A. Wade (2007)
10.1097/00004714-199312002-00003
A Double‐Blind, Randomized, Fluoxetine‐Controlled, Multicenter Study of Paroxetine in the Treatment of Depression
J. Tignol (1993)
uoxetine in major depression
C Akkaya (1993)
A double blind comparison of paroxetine and fl uoxetine in patients with major depression
CA Gagiano (1993)
10.4088/JCP.V67N1102
A randomized, double-blind, active-control study of sertraline versus venlafaxine XR in major depressive disorder.
R. Shelton (2006)
10.4088/JCP.V63N0410
Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.
W. Burke (2002)
uoxetine in the treatment of major depressive disorder: a double-blind, randomized trial
V Andreoli (2005)
A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The Venlafaxine French Inpatient Study Group.
G. Clerc (1994)
10.1097/01.yic.0000068045.82050.00
A randomized, double‐blind, 24‐week study comparing the efficacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care
A. Wade (2003)
uoxetine in the treatment of unipolar major depressive disorder
E Taner (2000)
10.1097/00004850-200501000-00010
Imputing response rates from means and standard deviations in meta-analyses
T. Furukawa (2005)
10.1097/01.JGP.0000194645.70869.3B
A double-blind, placebo-controlled study of venlafaxine and fluoxetine in geriatric outpatients with major depression.
A. Schatzberg (2006)
10.4088/JCP.V61N0911
Mirtazapine compared with paroxetine in major depression.
O. Benkert (2000)
10.1097/00004850-199911000-00002
Efficacy and tolerability of mirtazapine versus citalopram: a double-blind, randomized study in patients with major depressive disorder. Nordic Antidepressant Study Group.
E. Leinonen (1999)
10.1002/DEPR.3050030402
Double-blind multicenter comparison of fluvoxamine versus sertraline in the treatment of depressed outpatients
C. Nemeroff (1995)
10.1007/BF02245454
Controlled comparison of milnacipran and fluoxetine in major depression
M. Ansseau (2005)
10.4088/JCP.V61N1209
Efficacy and response time to sertraline versus fluoxetine in the treatment of unipolar major depressive disorder.
R. Suri (2000)
10.1016/S0149-2918(00)88317-4
A placebo-controlled comparison of the antidepressant efficacy and effects on sexual functioning of sustained-release bupropion and sertraline.
H. Croft (1999)
10.1111/j.1600-0447.1993.tb03345.x
A double‐blind, comparative, multicentre study comparing paroxetine with fluoxetine in depressed patients
J. Wilde (1993)
10.1097/01.yic.0000074988.54339.7c
Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care
A. Wade (2002)
10.1097/00004850-199805000-00005
A double‐blind comparison of the efficacy and safety of milnacipran and fluoxetine in depressed inpatients
J. Guelfi (1998)
10.2165/00044011-200727070-00005
Double-Blind Comparison of Escitalopram and Duloxetine in the Acute Treatment of Major Depressive Disorder
A. Khan (2007)
10.1097/00004850-199609000-00002
Efficacy and tolerability of citalopram in comparison with fluvoxamine in depressed outpatients: a double‐blind, multicentre study
P. J. Haffmans (1996)
10.1097/00004850-200015010-00004
Increased remission rates with venlafaxine compared with fluoxetine in hospitalized patients with major depression and melancholia
M. Tzanakaki (2000)
10.1177/0962280207080643
Evaluation of networks of randomized trials
G. Salanti (2008)
EPIC 014 Study Group. A double-blind, placebo-controlled comparison of venlafaxine and fl uoxetine treatment in depressed outpatients
CB Nemeroff (2007)
cacy and tolerability of mirtazapine and paroxetine in depressed patients in primary care
A Wade (2003)
10.1111/j.1600-0447.1988.tb05188.x
Paroxetine in the treatment of depression
C. Mertens (1988)
10.1590/S0101-60832009000800001
World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1: Acute and continuation treatment of major depressive disorder.
M. Bauer (2002)
[Table, CER 7 - Comparative Effectiveness of Second-Generation Antidepressants in the Pharmacologic Treatment of Adult Depression].
P. Shekelle (2009)



This paper is referenced by
10.1002/14651858.CD010219.pub2
Selective noradrenaline reuptake inhibitors for schizophrenia.
Paul R L Matthews (2018)
10.1186/1471-2288-13-35
A graphical tool for locating inconsistency in network meta-analyses
U. Krahn (2013)
Multicriteria benefit e risk assessment using network meta-analysis
Gert van Valkenhoefa ()
Dualni antidepresiv za dualnu dijagnozu - Liječenje venlafaksinom bolesnika oboljelog od PTSP-a u komorbiditetu s depresivnim poremećajem i abuzusom alkohola
S. Kezić (2010)
10.1093/ijnp/pyv060
Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis
X. Zhou (2015)
10.1159/000328768
Statistical Alchemy for Drug Treatment of Generalized Anxiety Disorder: A Commentary on the Meta-Analysis by Baldwin et al. [BMJ 2011;342:d1199]
G. Fava (2011)
10.1016/j.jad.2009.06.044
Canadian Network for Mood and Anxiety Treatments (CANMAT) clinical guidelines for the management of major depressive disorder in adults. I. Classification, burden and principles of management.
S. Patten (2009)
10.1016/b978-1-4377-1935-2.00052-1
Mental health and behavioral disorders in pregnancy.
Wisner Kl (2008)
Mirtazapine Review of its Use in Major Depression and Other
Wolters Kluwer (2009)
10.1136/ebmh.12.4.98
Are all antidepressants equal?
Gerald Gartlehner (2009)
10.1007/s11428-009-0534-6
Pharmakotherapie der Depression bei Menschen mit Diabetes
Kai G. Kahl (2009)
Developing and Evaluating a Psychological Intervention for use in Palliative Care
John M. Galfin (2011)
10.1037/a0029487
The ironic effect of significant results on the credibility of multiple-study articles.
U. Schimmack (2012)
10.1016/j.jad.2013.04.013
Public attitudes toward depression and help-seeking in four European countries baseline survey prior to the OSPI-Europe intervention.
E. Coppens (2013)
10.1016/B978-0-12-405170-6.00002-6
Meta-Analysis of Clinical Trials in Bipolar Disorder
John R. Geddes (2015)
Badania z randomizacją w psychiatrii Randomized controlled trials in psychiatry
M. Siwek (2012)
10.1192/APT.BP.114.014217
How have systematic reviews and meta-analyses benefited psychiatry?
Alex J Mitchell (2016)
10.1007/s15202-014-0632-1
Depression im Alter – Strategien für Diagnostik und Therapie
C. H. Waechtler (2014)
10.1055/S-0038-1669610
Pro and Contra: Selective Serotonin Reuptake Inhibitors for the treatment of major depression in patients with heart failure
C. Angermann (2015)
ADHD Medications: Cardiovascular Safety in Adults
Habel L (2012)
10.1136/bmj.f5133
Efficacy and safety outcomes of oral anticoagulants and antiplatelet drugs in the secondary prevention of venous thromboembolism: systematic review and network meta-analysis
L. Castellucci (2013)
10.1177/0272989X13487604
Evidence Synthesis for Decision Making 1
S. Dias (2013)
10.1017/S0790966700000331
Recent advances in the biological treatment of mood disorders.
G. McDonald (2009)
10.1016/j.clinthera.2011.11.024
Rates of 5 common antidepressant side effects among new adult and adolescent cases of depression: a retrospective US claims study.
H. Anderson (2012)
10.1177/0269881119840521
Mirtazapine attenuates anxiety- and depression-like behaviors in rats during cocaine withdrawal
Susana Barbosa Méndez (2019)
10.1016/j.jad.2020.04.010
Predicting second-generation antidepressant effectiveness in treating sadness using demographic and clinical information: A machine learning approach.
Amanda J. Lin (2020)
10.36290/med.2018.006
The most common mistakes in the treatment of depression in primary care
S. Racková (2018)
Assessment of Serotonergic Function by Radioligands and Microdialysis
A. Visser (2009)
10.1016/j.ejphar.2010.08.026
Sertraline increases extracellular levels not only of serotonin, but also of dopamine in the nucleus accumbens and striatum of rats.
Y. Kitaichi (2010)
10.1002/mpr.1381
Critical evaluation of mixed treatment comparison meta‐analyses using examples assessing antidepressants and opioid detoxification treatments
A. Schacht (2013)
Assessing the comparative-effectiveness of antidepressants commonly prescribed for depression in the US Medicare population.
Cameron M Kaplan (2012)
10.1007/s40258-018-0383-9
Long-Term Costs and Health Consequences of Issuing Shorter Duration Prescriptions for Patients with Chronic Health Conditions in the English NHS
A. Martin (2018)
See more
Semantic Scholar Logo Some data provided by SemanticScholar